Crop Announces Major 1.5 Million Pound 3-Year Supply Agreement
Momentum Public Relations
Press Release: October 23, 2018
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that Hempire, the Company’s brand and tenant at its 49% owned Nevada CBD farm, has signed a three-year, 500,000 pound per year (1,500,000 pounds total) supply agreement with deliveries starting August 2019.
The CBD flower is to be delivered in shipments of 50,000 dry pounds on a bi-monthly basis with payment to be made of $36.00 USD per pound to $57.00 USD per pound plus the cost of delivery depending on the CBD content indicated by the Certificate of Analysis. If market conditions change adversely in favor of, or against the company, the contract stipulates that prices will not fluctuate more than 25% over, or below, the range of $36 – $57 per pound.
Cannabis industry analysts, The Brightfield Group, estimate the hemp-CBD market alone could reach $22-billion by 2022.
CROP Infrastructure CEO, Michael Yorke, stated: “This is our first major supply contract and we have been extremely encouraged by the number of interested off-takers that have contacted us about our 2019 CBD crop as all of our 2018 harvest will be used to produce CBD isolate.”
“With CROP’s footprint now consisting of 1,865 acres with 1,340 acres of water rights under pivot, as announced on September 24th, we estimated 2019 tenant production at the Nevada CBD farm will be approximately 2,680,000 pounds, making this one supply agreement less than one-fifth of the total 2019 estimated production the Nevada CBD farms.”
The two existing strains planted during the 2018 season with up to 19 % CBD will be planted for 2019 along with three additional strains with similar CBD concentrations. The farm will be planted and maintained to organic standards to ensure the hemp-CBD is to the specification of interested buyers.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, an 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected yield from The Nevada Property; the technological effects of The Nevada Property on production; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Phone: +1(604)484-4206
Website: http://www.cropcorp.com
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
Fall Harvest Has Commenced at CROP’s CBD Farm in Nevada
Momentum Public Relations
Press Release: October 18, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) announces its 1,865 acre Nevada hemp-CBD farm has commenced harvest on the 240 acres planted in July and August of this year.
All equipment sourced for the 2018 harvest has now arrived at the property with commercial drying equipment en route. Upon completion of harvest and drying the company will begin delivering dried product to its processing partner, an ISO compliant processor, with bi-weekly shipments of CBD Isolate expected back to the company. The Isolate will be sold under white label as well as the company’s brands Hempire and Tiffany CBD.
According to cannabis industry analysts the Brightfield Group, it is estimated the hemp-CBD market alone could hit $22-billion by 2022.
The company is now accepting offers from interested hemp-CBD flower off-takers for its 2019 harvest as all 2018 production will be used for the production of CBD isolate.
The two existing strains planted during the 2018 season with up to 19% CBD will be planted for 2019 along with three additional genetics with similar CBD concentrations. The farm will be planted and maintained to organic standards to ensure the hemp-CBD is to the specification of interested buyers.
CROP Infrastructure Director and CEO, Michael Yorke, stated: “We are excited to be working with an ISO compliant processor to produce isolate while we work towards building our own in-house extraction capabilities. Having a full year of tenant production next year on the total acreage along with the strong uptrend in the CBD market should position the company, its tenants and its brands for a very exciting 2019.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, a 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
Crop adopts warrant exercise incentive program
Momentum Public Relations
Press Release: October 18, 2018
Crop Infrastructure Corp. (CROP:CSE) has adopted a warrant exercise incentive program, designed to encourage the early exercise of the company’s 17,439,055 outstanding common share purchase warrants with exercise prices and expiry dates as set out in the attached table.
Exercise Price Expire Date 2019-11-02 0.55 2020-06-20 0.75 2019-06-02 0.50 2019-12-11 0.50
The Program will be open for a 17-day period (the “Early Exercise Period”) beginning on October 17, 2018 and ending on November 2, 2018.
Pursuant to the Program, the Company is offering an inducement to each eligible holder of the Warrants (collectively, the “Warrant Holders”) that exercises the Warrants during the Early Exercise Period that consists of:
a reduced exercise price of $0.40 per common share; and
an additional common share purchase warrant (each an “Incentive Warrant”) for each Warrant exercised, with each Incentive Warrant entitling the Warrant Holder to purchase one additional common share of the Company until 5:00 p.m. (Vancouver time) on such date as is two years from the date of issuance of the Incentive Warrant at a price of $0.50 per common share.
The Company expects to use any proceeds received as a result of the Program for increasing the yield and efficiencies of each of its properties, development of retail outlets, project financing and general corporate purposes.
If Warrants are not exercised prior to the end of the Early Exercise Period or if a warrant holder does not qualify to receive Incentive Warrants, the Warrants will remain outstanding and continue to be exercisable on the same terms applicable to such Warrants as they existed prior to the Program.
The terms and conditions of the Program and the method of exercising Warrants pursuant to the Program will be set forth in a letter to be delivered to each warrant holder that the Company contacts. Warrant holders who wish to participate in the Program will agree to exercise their Warrants and deliver the other necessary documents in consideration of the issuance by the Company of the Incentive Warrants.
Only holders of Warrants who are “accredited investors” under applicable Canadian securities laws or who provide satisfactory evidence that they meet the requirements of an alternative exemption from the prospectus requirements of applicable Canadian securities laws may participate in the Program. U.S. holders of the Warrants are not eligible to participate in the Program. The Incentive Warrants will be subject to a four-month hold period from the date of the Incentive Warrant issuance pursuant to applicable Canadian securities laws. No fractional Incentive Warrants will be issued and the number of Incentive Warrants to be issued shall be rounded down to the nearest whole number.
The Company further announces that it has settled $570,000 in debt to multiple debtors for 1,200,000 common shares of the Company at a deemed price of $0.475 per common share. These common shares are subject to a 4 month hold period.
All numbers in Canadian dollars unless otherwise noted
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, a 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
We seek Safe Harbor.
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
Sirona Biochem Engages Consultant for Japanese Market Penetration
Momentum Public Relations
Press Release: October 17, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to announce that it has engaged Mr. Sven Harpering, a Tokyo-based consultant, with the help of its strategic advisory firm, PRC Partners (“PRC”) to fast-track negotiations in Japan.
Sven Harpering is a recognized Japanese business expert, with a Masters in East-Asian Studies. He has 14 years of business experience in Germany and 10 years in Japan, where he built a strong track record working in top management positions within various businesses.
With a deep insight of Japanese business culture and a high degree of fluency in Japanese, he is currently acting as a door-opener, consultant, intermediary and interpreter for a complex and demanding cross-section of businesses including; medical instruments, cosmetics, food and food-supplements.
The Company has appointed Mr. Harpering to build and negotiate licensing agreements for Sirona’s lead skin-lightening active TFC-1067 as well as its anti-wrinkle compound LIP-01, exclusively in Japan. Mr. Harpering will be working as a full time consultant for Sirona.
Asia continues to be the fastest growing market for skin-lightening, with high consumer purchasing power and a large demand for safe, effective products that are hydroquinone-free. Japan, specifically, is the largest skin-lightening market in the world, accounting for approximately 70% of the global market revenue, or 14 billion USD.
Sirona recognized the difficulty of penetrating the valuable Japanese market and elected to bring Mr. Harpering on board to capitalize on his extensive expertise in the market and his experience negotiating deals with government officials. Because he is based in Japan and speaks fluent Japanese, this will enable and expedite discussions with leading Japanese cosmetic companies.
“We are pleased to have Mr. Harpering representing Sirona in Japan and taking the lead in finding the right partners for TFC-1067 and LIP-01,” said Dr. Howard Verrico, CEO of Sirona Biochem. “It is essential we have an expert located in Japan who is familiar with the local business customs, can act quickly and has previously achieved success in negotiations in Japan. We believe this is the most cost-effective way to introduce Sirona to the large cosmetic companies in Japan and develop partnerships.”
Sirona remains focused on securing licensing agreements for TFC-1067 in North America and China. As discussions move forward, expanding Sirona’s market reach will ensure greater success for TFC-1067. With the assistance of PRC and the consultants in Japan and China, the Company believes it will be successful in licensing TFC-1067 in Asia, and North America.
About PRC Partners
PRC Partners is a Hong Kong-based corporate development consulting firm with a strong focus on China and Japan. The company assists Canadian public companies in tapping investment funds and high-net-worth individuals in Asia.
PRC Partners has a specific focus on the discovery of undervalued and promising growth companies and serves these companies by increasing visibility and accessing capital through an experienced network of investors.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
North Bud Farms Announces Creation of “1017” Distribution and Signing of a Letter of Intent to Acquire Cannabis Accessory Distributor and Product Developer Janey’s
Momentum Public Relations
Press Release: October 17, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) announces the creation of “1017” distribution and signing of a letter of intent to acquire Ontario cannabis store accessory distributor of Janey’s which operates as a subsidiary of Twelve Barrels Whiskey.
This Agreement provides that NORTHBUD will acquire ownership of assets related to Janey’s line of cannabis accessories and IP related to product development.
In exchange for these rights, Twelve Barrels Whiskey will receive 120,000 common shares of North Bud Farms at a deemed price of $0.40 per share.
NORTHBUD will provide the required capital investments to develop the proposed line of Janey’s products and may enter into revenue sharing agreements.
The companies intend to negotiate a definitive agreement within the next 30 days.
“This acquisition will provide a solid foundation for “1017” distribution,” said Ryan Brown, CEO and Founder of North Bud Farms Inc. “Janey’s brand was created as a platform for cannabis product development and distribution.”
Brown further stated, “With the acquisition of Janey’s brand NORTHBUD has secured an experienced product development and distribution partner with existing distribution into the Ontario Cannabis Store retail program.”
As per the terms of the Agreement, Cole Miller founder and sole owner of Janey’s brand and Twelve Barrels Whiskey will join the NORTHBUD team as product development manager.
“We are excited to have Cole lead this new division for both accessories and consumer product goods to be sold under our “1017” brand,” said Ryan Brown, CEO and Founder of North Bud Farms Inc.
“Our alcoholic beverages experience combined with NORTHBUD’s cannabis expertise and technology will allow our existing accessories brand to develop new products and expand into markets both domestically and abroad,” said Cole Miller, Founder of Janey’s.
Miller stated, “We are looking forward to working with NORTHBUD to further develop our line of cannabis-based beverages which are at a late stage in their development. As 1 of 10 accessories supplier to the Ontario Cannabis Store, we are well positioned to expand our product offering and gather consumer market data.”
About “1017” Brands
“1017” Brands has been established as a development and distribution platform for cannabis products and accessories. NORTHBUD intends to develop multiple products over a variety of product segments under the “1017” brand.
In August 2018 NORTHBUD successfully filed a trademark application for the use of the words and numbers “1017” as it relates to the global cannabis industry. The filing of this trademark gives NORTHBUD priority over the use of “1017” which we believe will become an iconic symbol in the Canadian cannabis industry.
“Branding will play an important role in establishing both product and company identity,” said Ryan Brown, CEO and Founder of North Bud Farms Inc. “October 17, 2018 represents a historic day in the history of Cannabis in Canada and NORTHBUD is proud to be able to carry that moniker moving forward. Over the next 12 months NORTHBUD intends to develop multiple consumer products to be sold under the “1017” brand.”
About Janey’s Inc.
Janey’s Inc. is a subsidiary of Twelve Barrels Whiskey Inc., an Ontario corporation. Janey’s is one of six approved Cannabis accessory suppliers to the Ontario cannabis store.
For more information visit: https://twelvebarrels.com/
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Business, Life Sciences, Marijuana, Medical Marijuana, News Home, NorthBud
Sirona Biochem Announces Close of Financing and Extension of Convertible Notes
Momentum Public Relations
Press Release: October 17, 2018
Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (the “Company”) announced that it has closed a private placement (subject to TSX.V approval) in the amount of 7,095,100 units at $0.10 per unit for total gross proceeds of $709,510. Each unit consists of one common share and one transferable share purchase warrant. Each whole warrant is exercisable into one additional common share of the Company for a period of three years, from the date of issue, at a price of $0.18 per share.
The Company paid a total of $9,532 in finder’s fees in connection with the placement.
“We are very pleased that we have ongoing support from our existing shareholders as well as interest from new parties,” said Howard Verrico, CEO. “The funds will go toward the upcoming clinical trial, international partnering activities, paying off a portion of existing convertible notes, as well as general operating expenses.”
All securities issued under the placement are subject to statutory hold periods expiring on February 16, 2019.
The Company also announced that it extended $443,600 of the $665,360 convertible notes that matured August 31, 2018. Each Note will be extended for a 12 month term, convertible at the option of the holder into one common share of the company at a conversion price of $0.14 per share.
The Notes will bear interest at the rate of 12% per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period. The Notes are unsecured and transferable, subject to resale restrictions under applicable securities laws and TSX Venture Exchange requirements.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
North Bud Farms Provides a Corporate Update
Momentum Public Relations
Press Release: October 16, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders an update on our corporate activities.
Construction of Our Cannabis Production Facility in Low, Quebec:
NORTHBUD and its team have been hard at work finalizing some minor design changes to our proposed facility located on 95 acres of agricultural land in Low, Quebec. NORTHBUD has received a detailed timeline for construction from our builder, NGA Construction Inc., and is on schedule to have the facility completed and an evidence package submitted to Health Canada in Q1 2019. We are pleased to report the facility budget is on target.
All infrastructure implementation has been completed and physical facility construction will begin, October 17, 2018.
ACMPR Application:
As previously disclosed in our prospectus, NORTHBUD, through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). In this regard, NORTHBUD has engaged Cannabis Compliance Inc. to assist in the migration of the ACMPR application to the CLTS which goes into effect after the implementation of the Cannabis Act on October 17, 2018. NORTHBUD will be making amendments in order to take advantage of favourable changes that have been implemented under the Cannabis Act.
Key New Hires:
NORTHBUD is pleased to announce the hiring of Magda Farid who will serve as our head of Quality Assurance and Compliance. Ms. Farid previously served as head of quality assurance for HEXO Corp. (formerly known as The Hydropothecary Corporation), a licensed producer under the ACMPR, in addition to multiple roles as Quality Assurance Manager in the pharmaceutical industry with companies such as McKesson and Trillium Health Care Products Inc. Ms. Farid has a Bachelor of Science degree from the University of Ottawa with a double major in biochemistry and nutrition.
“NORTHBUD is very pleased to be able to bring on a quality assurance manager with experience in both the cannabis and pharmaceutical industries,” said Ryan Brown, CEO and Founder of North Bud Farms Inc. “This decision was made to bring in a new Quality Assurance Manager as we believe that a combination of experience in pharmaceutical and cannabis is critical for NORTHBUD to execute on its strategy to be a strategic supplier of Pharmaceutical and Food grade cannabis inputs. We are focused on strengthening our team to be prepared for Legalization 2.0 as well as exploring opportunities to accelerate our development and provide value to shareholders.”
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Business, Life Sciences, Medical Marijuana, News Home
Next Green Wave Holdings Inc. announces proposed acquisition of Loud Seeds – a High Times Hall of Fame inductee
Momentum Public Relations
Press Release: October 16, 2018
Next Green Wave Holdings Inc. (CSE : NGW) (“Next Green Wave” or the “Company“), is pleased to announce that it has entered into a letter of intent (“LOI“) whereby the Company intends to acquire 100% of Loud Seeds, LLC (“Loud Seeds”) along with the Loud Seeds brand and all of its related assets (the “Transaction“). As consideration for the Transaction, Next Green Wave intends to distribute $2,000,000 in common shares of the Company to the shareholders of Loud Seeds. Completion of the Transaction is subject to the satisfaction of a number of conditions, including completion of due diligence by the Company, obtaining all required regulatory approvals.
Michael Jennings, CEO and Director of NGW, is a principle in Loud Seeds. The Transaction is therefore a related party transaction and will be subject to the requirements of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. The Transaction was approved by all the independent directors.
Loud Seeds is a multiple cannabis cup winner for its seeds and clones, has flourished as innovators in developing premium quality cannabis products to meet the dynamic consumer demands. The principles over the past 20 years have developed a vast collection of award-winning strains and has been inducted into the High Times Hall of Fame and the Top 40 Seed Banks of all time.
KEY HIGHLIGHTS
- Loud Seeds brings an extensive catalogue of cannabis genetics into Next Green Wave accelerating its nursery and cultivation ability
- Loud Seeds is a six-time High Times Cannabis Cup winner
- Loud Seeds has been inducted into the High Times Hall of Fame and listed in the Top 40 Seed Banks of all time
James Load (Principle / Founder) of Loud Seeds: “We are excited to bring our extensive portfolio into Next Green Wave, who’s vision and innovative nursery and cultivation style will see our Loud Seeds genetic library go to the next level. Next Green Wave’s cannabis platform is exceptional and their vision to be a dominate force in California and other jurisdictions is exciting for Loud Seeds.”
Leigh Hughes, Executive Chairman of Next Green Wave:“Being able to bring one of the best seed banks in the world into our nursery continues to differentiate Next Green Wave from other cultivators. “We are excited to join an award-winning genetics portfolio with world-class breeding skills as the construction of our first facility nears completion and begins cultivation.”
ABOUT LOUD SEEDS, LLC
Loud Seeds was founded by Kenneth James Koskiniemi (aka: James Loud) and Michael Jennings (aka: Mike Seeds) who have been growing and breeding premium cannabis for over 20 years with a focus on organic growing. Over that time, Loud Seeds has developed a vast collection of cannabis strains and worked with some of the finest cultivators in the United States and Europe on innovative growing techniques and breeding projects.
Loud Seeds has been inducted into the High Times Hall of Fame and listed in the Top 40 Seed Banks of all time. Being covered in the press by The Million Dollar Grow Room, America’s Next Pot Kings and the Top Ten Strains of the Year, the Loud Seeds brand is one of the more recognized seed brands in California. Loud Seeds have breeding methods that have been developed for over 20 years and are specialists in creating, launching and marketing new strains based on consumer demand. Loud Seeds has also built a strong distribution list in California along with relationships with many other well-known cultivators and breeding partners.
ABOUT NEXT GREEN WAVE HOLDINGS INC.
Headquartered in Western Canada, Next Green Wave is a vertically integrated premium medicinal and recreational cannabis company operating in California, one of the world’s largest cannabis markets. Led by award-winning cannabis industry veteran Michael Jennings and an industry innovator specializing in premium cannabis products. The Company has plans to build four facilities centrally located on 15.5 acres of land in Coalinga, California allowing for state-wide reach across the lucrative California market.
For information on Next Green Wave please visit www.nextgreenwave.com/investors. For copies of news releases and all company materials please refer to SEDAR (www.sedar.com). For all investor relations information, please refer to www.nextgreenwave.com/investors or contact IR@nextgreenwave.com or +1 778-589-5054.
- Published in Business, Life Sciences, Medical Marijuana, News Home
Tetra Bio-Pharma Names Dr. Guy Chamberland as Chief Executive Officer and Chief Scientific Officer
Momentum Public Relations
Press Release: October 15, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the permanent appointment of Guy Chamberland, Ph.D., as CEO and CSO having most recently held the position of CEO in an interim capacity. Dr. Chamberland has more than 23 years’ experience in the development of new drugs in the North American pharmaceutical industry. He worked for more than 10 years as an executive with several biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years. Since joining Tetra Bio-Pharma in June 2016, Dr. Chamberland and his team have accomplished numerous milestones. These include having:
- Built a solid pipeline of five cannabinoid-based therapeutics using a variety of delivery mechanisms focused on a number of different disease indications many representing billion dollar markets;
- Developed an innovative regulatory strategy for each of these products to maximize approval success – thereby rapidly building shareholder value;
- Taking Tetra’s lead product PPP001 from concept to Phase 3 in less than two years and at 20 percent of the cost of a typical bio-pharma company;
- Taken the first smokable product into a Phase I and Phase III clinical trial;
- Structured company activities in three distinct commercial divisions: bio-pharma, natural health and veterinary medicine;
- Negotiated a major supply agreement with a well-established player in the natural health products market; and
- Increased the company’s share price more than 50% since assuming the role of interim CEO.
“We are extremely pleased with the progress that Guy has made since joining the company in 2016 and equally impressed with his accomplishments since being named interim CEO,” stated Tetra Bio-Pharma’s Chairman of the Board, Bill Cheliak. “It is for these reasons that the Board unanimously voted to permanently appoint Guy to the position of CEO, along with his role as Chief Scientific Officer. We look forward to seeing Guy and his team build on the tremendous momentum they have generated thus far and continue to increase shareholder value.”
“I am greatly honored by this nomination as well as by the confidence that the Board of Directors has shown in me,” said Dr. Chamberland. “As the CEO of Tetra Bio-Pharma I am excited and deeply committed to lead our team through the next stages of development. We are confident that our innovative pipeline of cannabis and cannabinoid products will play an important role in improving the lives of patients suffering from a range of chronic and acute pain conditions and have a significant impact in opioid sparing and/or replacement. It is evident that the pharmaceutical pathway that we are championing in order to establish the scientific evidence that regulators, the medical community and payers in Canada, the United States and Europe require in order to approve cannabis-based products is becoming better understood and increasingly welcomed. Our robust activity in the natural health sector further demonstrates our capacity for innovation.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma